Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis.

Neoplasia : an International Journal for Oncology Research
Tatsuma OkazakiHiroyuki Arai

Abstract

Erythropoietin (Epo), a known hematopoietic growth factor, has been reported to promote tumor growth and angiogenesis in Epo receptor (EpoR)-positive tumors, but its effects on EpoR-negative tumors have not been clearly shown. Here, we show that Epo accelerates the growth of EpoR-negative tumors by promoting tumor angiogenesis. Mice were inoculated with Lewis lung carcinoma cells and treated with Epo. Erythropoietin accelerated tumor growth and increased intratumoral microvessel density, although it did not accelerate Lewis lung carcinoma cell tumor proliferation in vitro. To observe the direct effect of Epo on endothelial cells, we examined human dermal microvascular endothelial cells (HMVECs) that expressed EpoR. Erythropoietin induced the proliferation of HMVECs and protected them from H2O2-induced cell death. Erythropoietin activated the extracellular signal-regulated kinase signaling pathway and up-regulated the expression of the downstream antiapoptotic protein Bcl-xL in HMVECs. Moreover, in both the absence and presence of tumors, in vivo treatment of mice with Epo increased circulating endothelial progenitor cells. To investigate the role of Epo in a primary tumor model, we inoculated the chemical carcinogen methylchola...Continue Reading

Citations

Nov 6, 2009·Stem Cells and Development·Domenico Ribatti
Jul 9, 2010·Journal of Neuro-oncology·Beatrice NicoDomenico Ribatti
Dec 7, 2011·Journal of Internal Medicine·J BachmannU Klingmüller
Nov 17, 2011·International Journal of Oncology·Jinsheng YangBo Fan
Jan 18, 2014·The Journal of Clinical Investigation·Bing ZhouWilliam Y Kim
Aug 6, 2013·International Journal of Cancer. Journal International Du Cancer·Soulafa MamloukBen Wielockx
Jul 19, 2013·PloS One·Steve ElliottCarol Johnson
Nov 27, 2014·Frontiers in Immunology·Nataša DebeljakArthur J Sytkowski
Jul 14, 2017·International Journal of Molecular Sciences·Patrícia KimákováNataša Debeljak
Nov 26, 2010·Pharmacological Reports : PR·Anna Tankiewicz-KwedloWłodzimierz Buczko
May 10, 2013·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Kaijun NiuRyoichi Nagatomi
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brandon K Hadland, Gregory D Longmore
Jun 12, 2009·Critical Reviews in Toxicology·Julie E GoodmanSagar Thakali
Aug 23, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin D HedleyAnargyros Xenocostas
Jul 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin D HedleyAnargyros Xenocostas
Oct 21, 2015·Cancer Cell·Sunila PradeepAnil K Sood
Apr 9, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Liasmine HaineNicolas Voituron
Sep 30, 2018·Advanced Drug Delivery Reviews·Austin P VeithAaron B Baker
May 4, 2021·Saudi Journal of Biological Sciences·Hareth Y ShujaaEdinAl-Shwyeh Hussah Abdullah
Jan 10, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Dennis DoleschelWiltrud Lederle
Nov 3, 2021·Protein Engineering, Design & Selection : PEDS·Jungmin LeePamela A Silver
Aug 25, 2010·Pharmacology & Therapeutics·L VellyP Pisano

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.